TrialNature medicine2023

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.

Joris van de Haar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.